What FDA approved
FDA posted the approval on November 13, 2026, and Genentech announced it November 15. The new indication is for adults with primary membranous nephropathy who are at risk of progression. Obinutuzumab is a CD20-directed antibody, and the indication’s treatment goal is remission of proteinuria.1234
In the open-label trial FDA reviewed, 142 adults were randomized to obinutuzumab or tacrolimus. At week 104, 36% of adults in the obinutuzumab arm and 6% in the tacrolimus arm met the trial definition of complete remission. That endpoint included low urinary protein and stable estimated kidney function.1
Preparing an infusion order
The prescribing information specifies an initial infusion and doses at weeks 2, 24, and 26. It calls for hepatitis B screening before treatment and includes precautions for infusion reactions. The boxed warning covers hepatitis B reactivation and progressive multifocal leukoencephalopathy.2
Chad’s analysis. An indication-specific order set can help prevent selection of another Gazyva regimen. The infusion team can confirm that the payer authorization reflects the new indication and intended dosing schedule, then check that screening, premedication, and monitoring are in place before scheduling.
Source notes
- U.S. Food & Drug Admin., FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy (Nov. 13, 2026).
- Genentech, Inc., Gazyva Prescribing Information §§ 1.5, 2.6–2.7, 5.1–5.3, 12.1 (rev. Nov. 2026).
- U.S. Food & Drug Admin., Notable Approvals (listing the Gazyva notice posted Nov. 13, 2026).
- Genentech, Inc., Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy (Nov. 15, 2026).